CN101001874B - 聚-n-乙酰葡萄糖胺(pnag/dpnag)结合肽及其应用方法 - Google Patents

聚-n-乙酰葡萄糖胺(pnag/dpnag)结合肽及其应用方法 Download PDF

Info

Publication number
CN101001874B
CN101001874B CN2005800203560A CN200580020356A CN101001874B CN 101001874 B CN101001874 B CN 101001874B CN 2005800203560 A CN2005800203560 A CN 2005800203560A CN 200580020356 A CN200580020356 A CN 200580020356A CN 101001874 B CN101001874 B CN 101001874B
Authority
CN
China
Prior art keywords
pnag
antibody
seq
dpnag
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800203560A
Other languages
English (en)
Chinese (zh)
Other versions
CN101001874A (zh
Inventor
G·B·皮埃尔
C·A·凯利-奎因托斯
L·卡维齐尼
M·R·波斯纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Beth Israel Deaconess Medical Center Inc
Original Assignee
Brigham and Womens Hospital Inc
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Beth Israel Deaconess Medical Center Inc filed Critical Brigham and Womens Hospital Inc
Publication of CN101001874A publication Critical patent/CN101001874A/zh
Application granted granted Critical
Publication of CN101001874B publication Critical patent/CN101001874B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2005800203560A 2004-04-21 2005-04-21 聚-n-乙酰葡萄糖胺(pnag/dpnag)结合肽及其应用方法 Expired - Fee Related CN101001874B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56410504P 2004-04-21 2004-04-21
US60/564,105 2004-04-21
PCT/US2005/013694 WO2005103084A2 (en) 2004-04-21 2005-04-21 Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof

Publications (2)

Publication Number Publication Date
CN101001874A CN101001874A (zh) 2007-07-18
CN101001874B true CN101001874B (zh) 2012-12-19

Family

ID=35197541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800203560A Expired - Fee Related CN101001874B (zh) 2004-04-21 2005-04-21 聚-n-乙酰葡萄糖胺(pnag/dpnag)结合肽及其应用方法

Country Status (12)

Country Link
US (13) US7786255B2 (https=)
EP (6) EP2455400B1 (https=)
JP (2) JP5080243B2 (https=)
CN (1) CN101001874B (https=)
AU (1) AU2005236068C1 (https=)
CA (1) CA2567748A1 (https=)
DK (1) DK1745075T3 (https=)
ES (2) ES2415358T3 (https=)
PL (1) PL1745075T3 (https=)
PT (1) PT1745075E (https=)
SI (1) SI1745075T1 (https=)
WO (1) WO2005103084A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7047058B1 (en) 2001-02-06 2006-05-16 Medrad, Inc. Apparatuses, systems and methods for extravasation detection
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
ES2415358T3 (es) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
AU2012268821B2 (en) * 2006-06-06 2016-06-02 Janssen Vaccines & Prevention B.V. Human binding molecules having killing activity against staphylococci and uses thereof
CA2881717C (en) * 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
WO2013033174A1 (en) 2011-09-02 2013-03-07 Battelle Memorial Institute Extravasation and infiltration detection device
WO2013075740A1 (en) * 2011-11-23 2013-05-30 Sanofi Antibody purification method
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
CN104955840A (zh) * 2012-08-24 2015-09-30 赛诺菲 抗多聚n-乙酰葡糖胺(pnag)单克隆抗体及其用于预防或治疗表达pnag的细菌感染的用途
WO2014050518A1 (ja) 2012-09-28 2014-04-03 日本電気株式会社 情報処理装置、情報処理方法および情報処理プログラム
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
JP6371758B2 (ja) * 2013-03-12 2018-08-08 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
EP3301115B1 (en) 2013-05-06 2021-11-10 Sanofi Continuous multistep process for purifying antibodies
EP2889311B1 (en) * 2013-12-30 2018-03-21 Albert-Ludwigs-Universität Freiburg Opsonic and protective monoclonal antibodies against gram-positive pathogens
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
CN110891596A (zh) 2017-05-04 2020-03-17 希望之城 抗体可变结构域及抗体构建体
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
CN110184231B (zh) * 2019-05-31 2021-02-12 杭州丰海生物科技有限公司 一种胞外分泌pnag多糖的重组枯草芽孢杆菌及其应用
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
JP2023502276A (ja) * 2019-11-22 2023-01-23 アロペックス・インコーポレイテッド Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US213668A (en) 1879-03-25 Improvement in ice-making apparatus
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) * 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) * 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) * 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) * 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
EP0449958B9 (en) 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
WO1993001276A1 (en) 1991-07-12 1993-01-21 Smithkline Beecham Corporation Continuous cell line and vaccine against avian coccidia
ES2198405T3 (es) 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
WO1993010847A1 (en) * 1991-12-06 1993-06-10 North Shore University Hospital Research Corporation Method of reducing medical device related infections
CA2132421C (en) 1992-03-19 2010-11-23 Gerald W. Fischer Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) * 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5718694A (en) * 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
PT699237E (pt) * 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5830539A (en) * 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
US6245735B1 (en) * 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
EP0962467A4 (en) * 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) * 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
CA2319089A1 (en) * 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
WO2000002745A1 (en) 1998-07-11 2000-01-20 Mile High Marketing Limited Vehicle seat, vehicle seat table and vehicle communication system
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
DK1096952T3 (da) * 1998-07-15 2008-08-25 Brigham & Womens Hospital Polysaccharidvaccine mod stafylokok-infektioner
ATE483480T1 (de) 1998-12-16 2010-10-15 Tno Saure superabsorbierende polysaccharide
AU2002309567A1 (en) * 2001-05-16 2002-12-03 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US6962813B2 (en) * 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US7119172B2 (en) * 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
WO2003053462A2 (en) 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
EP1470146B8 (en) * 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004042407A1 (en) 2002-11-04 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 73a (gpr73a)
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
ES2415358T3 (es) 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog
EP1844136B1 (en) 2004-12-29 2014-08-27 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
CN102387808A (zh) 2009-02-20 2012-03-21 有限公司名将 免疫增强组成物及其制造方法
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
RU2019101166A (ru) 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US9759721B2 (en) 2013-01-22 2017-09-12 Imicroq, S.L. Rapid method for detection of pathogen

Also Published As

Publication number Publication date
US8410249B2 (en) 2013-04-02
US9458227B2 (en) 2016-10-04
US20120201833A1 (en) 2012-08-09
US8912314B2 (en) 2014-12-16
US8461319B2 (en) 2013-06-11
EP2455400A1 (en) 2012-05-23
SI1745075T1 (sl) 2013-07-31
AU2005236068A1 (en) 2005-11-03
EP2455401B1 (en) 2018-01-24
US20230382980A1 (en) 2023-11-30
US8350017B2 (en) 2013-01-08
WO2005103084A3 (en) 2006-02-16
EP2455401A1 (en) 2012-05-23
EP2455402A1 (en) 2012-05-23
ES2738112T3 (es) 2020-01-20
AU2005236068B2 (en) 2012-04-26
JP5717582B2 (ja) 2015-05-13
WO2005103084A2 (en) 2005-11-03
EP2468769A1 (en) 2012-06-27
US20060115486A1 (en) 2006-06-01
US20210363228A1 (en) 2021-11-25
CN101001874A (zh) 2007-07-18
US7786255B2 (en) 2010-08-31
US20130243806A1 (en) 2013-09-19
EP1745075A2 (en) 2007-01-24
EP1745075B1 (en) 2013-04-03
US20170226194A1 (en) 2017-08-10
HK1100369A1 (en) 2007-09-21
JP2011224023A (ja) 2011-11-10
CA2567748A1 (en) 2005-11-03
ES2415358T3 (es) 2013-07-25
EP2439213B1 (en) 2018-12-12
US20150329620A1 (en) 2015-11-19
US20120201834A1 (en) 2012-08-09
US20110002932A1 (en) 2011-01-06
US20110274700A1 (en) 2011-11-10
JP2008501317A (ja) 2008-01-24
EP2439213A1 (en) 2012-04-11
US10017563B2 (en) 2018-07-10
US8252894B2 (en) 2012-08-28
US20120208270A1 (en) 2012-08-16
JP5080243B2 (ja) 2012-11-21
US20120196359A1 (en) 2012-08-02
PL1745075T3 (pl) 2013-09-30
AU2005236068C1 (en) 2012-08-30
PT1745075E (pt) 2013-06-17
US8084595B2 (en) 2011-12-27
US20190127448A1 (en) 2019-05-02
US10906962B2 (en) 2021-02-02
EP2455400B1 (en) 2019-03-20
US8435515B2 (en) 2013-05-07
DK1745075T3 (da) 2013-06-24

Similar Documents

Publication Publication Date Title
US20230382980A1 (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
AU2012205180B2 (en) Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
AU2014277807B2 (en) Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
HK1169423A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
HK1171762A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding antibodies
HK1168859A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
HK1172044A (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121219

Termination date: 20210421